Severe reaction to 5% imiquimod cream with excellent clinical and cosmetic outcomes.
Imiquimod, an immune response modifier approved for the treatment of external genital warts, actinic keratoses, and superficial basal cell carcinoma, can induce a severe local inflammatory response. This phenomenon can accompany inappropriately overzealous, as well as entirely conventional, drug utilization. Despite strikingly brisk reactions, the 9 patients reported herein ultimately experienced excellent cosmetic and clinical outcomes. We report this series to alert clinicians of the good prognosis for a satisfactory outcome even when faced with extreme imiquimod cream-induced inflammation.
Division of Dermatology, Scott & White Memorial Hospital and Clinic,; Scott, Sherwood and Brindley Foundation, Texas A&M University System Health Science Center, College of Medicine, Temple, TX, USA.
H L
HL
Greenberg
Joel L
JL
Cohen
Ted
T
Rosen
Ida
I
Orengo
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry; D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000634:Aminoquinolines / Q000008:administration & dosage / Q000009:adverse effects* / Q000737:chemistry; D002613:Cheilitis / Q000139:chemically induced / Q000188:drug therapy; D003875:Drug Eruptions / Q000188:drug therapy / Q000209:etiology*; D005260:Female; D006801:Humans; D000077271:Imiquimod; D007642:Keratosis / Q000139:chemically induced / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009824:Ointments; D013997:Time Factors; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D000634:Aminoquinolines; D009824:Ointments; D000077271:Imiquimod